# Antitumor Effects of PD-1 Blockade Combined with Mild Hyperthermia in a Murine Osteosarcoma Model

**Authors:** Yuya Izubuchi, Naoi Hosoe, Takaaki Tanaka, Yumiko Watanabe, Tatsunobu Kobayashi, Hideaki Nakajima, Hiroyasu Kidoya, Akihiko Matsumine

PMC · DOI: 10.3390/biomedicines14020341 · Biomedicines · 2026-02-01

## TL;DR

Combining PD-1 blockade with mild hyperthermia improves tumor suppression and immune response in a mouse model of osteosarcoma.

## Contribution

Demonstrates that mild hyperthermia enhances the antitumor effects of PD-1 blockade in osteosarcoma through immune modulation.

## Key findings

- Combination therapy significantly suppressed tumor growth and reduced lung metastasis in mice.
- Survival rates improved significantly in mice receiving combination therapy.
- Immune profiling showed increased CD8+ T cells and pro-inflammatory macrophage profiles.

## Abstract

Background: Osteosarcoma remains largely refractory to immune checkpoint inhibitor (ICI) monotherapy, and strategies to modulate the tumor immune microenvironment are being actively explored. Mild hyperthermia has been reported to influence antitumor immune responses; however, its impact in combination with PD-1 blockade in osteosarcoma has not been well characterized. Methods: Murine LM8 osteosarcoma cells were subjected to mild thermal stimulation, and changes in PD-L1 expression were evaluated. LM8-bearing mice were treated with mild hyperthermia, anti-PD-1 antibody, or their combination. Tumor growth, lung metastasis, and survival were assessed. Tumor-infiltrating immune cells were profiled using single-cell RNA sequencing to descriptively characterize immune-associated transcriptional features under each treatment condition. Results: Mild thermal stimulation (42 °C, 30 min) increased PD-L1 expression in LM8 cells in vitro. In vivo, combination therapy significantly suppressed primary tumor growth compared with control (χ2 = 29.75, p = 1.6 × 10−6) and reduced lung metastasis burden, with a significant decrease in metastatic nodules (p < 0.01). Kaplan–Meier analysis demonstrated a significant survival benefit in the combination group (log-rank p < 0.001). Single-cell RNA sequencing revealed an increased proportion of CD8+ T cells with reduced exhaustion-associated gene expression and a shift toward pro-inflammatory (M1-like) macrophage transcriptional profiles. Conclusions: PD-1 blockade combined with mild hyperthermia was associated with enhanced antitumor efficacy and immune-associated transcriptional remodeling in a murine osteosarcoma model, supporting further preclinical evaluation of this combination strategy.

## Linked entities

- **Genes:** CD274 (CD274 molecule) [NCBI Gene 29126]
- **Diseases:** osteosarcoma (MONDO:0002623)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Nos2 (nitric oxide synthase 2, inducible) [NCBI Gene 18126] {aka MAC-NOS, NOS-II, Nos-2, Nos2a, i-NOS, iNOS}, Th (tyrosine hydroxylase) [NCBI Gene 21823], PDCD1 (programmed cell death 1) [NCBI Gene 100533201], Arg1 (arginase, liver) [NCBI Gene 11846] {aka AI, Arg-1, PGIF}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Dnase1 (deoxyribonuclease I) [NCBI Gene 13419] {aka DNaseI, Dnl1}, Cd274 (CD274 antigen) [NCBI Gene 60533] {aka A530045L16Rik, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Mgl2 (macrophage galactose N-acetyl-galactosamine specific lectin 2) [NCBI Gene 216864] {aka CD301b}, LAG3 (lymphocyte activating 3) [NCBI Gene 100125962] {aka CD223, LAG-3}, TOX (thymocyte selection associated high mobility group box) [NCBI Gene 100155888], CD4 (CD4 molecule) [NCBI Gene 404704], Il2 (interleukin 2) [NCBI Gene 16183] {aka Il-2}, CD8A (CD8 subunit alpha) [NCBI Gene 396627], Pdcd1 (programmed cell death 1) [NCBI Gene 18566] {aka Ly101, PD-1, Pdc1}, LOC100513601 (patr class I histocompatibility antigen, A-126 alpha chain-like) [NCBI Gene 100513601] {aka PA1, PD1, SLA-1, SLA-1a, SLA-1b, SLA-P1}, Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, Mrc1 (mannose receptor, C type 1) [NCBI Gene 17533] {aka CD206, MR}, Ighv1-9 (immunoglobulin heavy variable 1-9) [NCBI Gene 668478] {aka Gm16697, Igg2a}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, Stat3 (signal transducer and activator of transcription 3) [NCBI Gene 20848] {aka 1110034C02Rik, Aprf}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}
- **Diseases:** cytotoxicity (MESH:D064420), weight loss (MESH:D015431), lung (MESH:D008171), Tumor (MESH:D009369), pain (MESH:D010146), bone tumor (MESH:D001859), injury to (MESH:D014947), OS (MESH:D012516), inflammatory (MESH:D007249), malignant melanoma (MESH:D008545), Lung Metastasis (MESH:D009362), head and neck squamous cell carcinoma (MESH:D000077195), non-small cell lung cancer (MESH:D002289), renal cell carcinoma (MESH:D002292), hepatocellular carcinoma (MESH:D006528), soft tissue sarcomas (MESH:D012509), HT (MESH:D005334), necrosis (MESH:D009336), mammary tumor (MESH:D015674), gastric cancer (MESH:D013274), breast cancer (MESH:D001943), bleeding (MESH:D006470)
- **Chemicals:** corticosterone (MESH:D003345), polyacrylamide (MESH:C016679), oil (MESH:D009821), catecholamines (MESH:D002395), pembrolizumab (MESH:C582435), doxorubicin (MESH:D004317), chitosan (MESH:D048271), Ionomycin (MESH:D015759), hematoxylin (MESH:D006416), DMEM (-), cisplatin (MESH:D002945), paraffin (MESH:D010232), trypan blue (MESH:D014343), H&amp;E (MESH:D006371), Percoll (MESH:C016039), reactive oxygen species (MESH:D017382), nivolumab (MESH:D000077594), eosin (MESH:D004801), PBS (MESH:D007854), PVDF (MESH:C024865), SDS (MESH:D012967), paraformaldehyde (MESH:C003043), isoflurane (MESH:D007530), Water (MESH:D014867), methotrexate (MESH:D008727), CO2 (MESH:D002245)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** LM8 — Mus musculus (Mouse), Mouse osteosarcoma, Cancer cell line (CVCL_6669), MDA-MB-231 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12937843/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12937843/full.md

## References

52 references — full list in the complete paper: https://tomesphere.com/paper/PMC12937843/full.md

---
Source: https://tomesphere.com/paper/PMC12937843